# How Long Has Semaglutide Been Around? What Research Shows

**By TelosRX Editorial Team** · 2026-11-11

**How long has semaglutide been around? Semaglutide has been FDA-approved since December 2017, when Ozempic launched for type 2 diabetes. Its research story is older, starting with GLP-1 discoveries in the 1980s. [TelosRX](https://telosrx.com) breaks down that timeline below.**

Semaglutide feels new because it went mainstream fast. The science underneath it is not new at all. It sits on roughly 40 years of gut-hormone research, a decade of drug design, and some of the largest outcome trials in metabolic medicine.

This review walks through what the research actually shows, one milestone at a time. Every finding links to its source. Nothing here is a promise of personal results.

## Semaglutide at a Glance: The Research Timeline

Here's the short version before the details. Dates are US FDA actions unless noted.

| Year | Milestone | Why it matters |
| --- | --- | --- |
| 1980s | GLP-1 hormone identified in the human gut | The biological target semaglutide copies |
| 2005 | First GLP-1 drug (exenatide) approved | Proved the drug class could work in people |
| 2008 | Phase 2 trials of once-weekly semaglutide begin | Start of human testing |
| 2016 | SUSTAIN-6 cardiovascular safety trial published | First large heart-outcome data |
| 2017 | Ozempic approved for type 2 diabetes | Semaglutide reaches the market |
| 2019 | Rybelsus approved (oral tablet) | First GLP-1 pill |
| 2021 | Wegovy approved for chronic weight management | Weight becomes a primary indication |
| 2024 | Wegovy gains a cardiovascular risk-reduction indication | Based on the SELECT trial |
| 2025 | Kidney (FLOW), liver (MASH) and oral weight-management approvals | Uses expand beyond blood sugar and weight |

So the answer depends on what you count. As a marketed drug, semaglutide is about nine years old. As a research program, it's closer to 20. As a hormone story, it's 40.

## Finding 1: The GLP-1 Hormone Was Discovered in the 1980s

GLP-1 stands for glucagon-like peptide-1. It's a hormone your gut releases after you eat. Researchers identified it in the mid-1980s while studying the glucagon gene.

Early work showed GLP-1 nudges the pancreas to release insulin when blood sugar rises. It also slows stomach emptying and signals fullness to the brain. Those three effects are still the core of how semaglutide works today.

The catch? Natural GLP-1 breaks down in about two minutes. That made it useless as a drug. The next 20 years were about making it last longer.

## Finding 2: Semaglutide Was Engineered to Last a Week

The first GLP-1 drug, exenatide (Byetta), reached the US market in 2005. It needed twice-daily shots. Liraglutide followed in 2010 as a once-daily option.

Semaglutide was designed as the next step. Chemists at Novo Nordisk modified the GLP-1 structure in three key ways:

-   **Amino acid swap** — blocks the enzyme (DPP-4) that normally chops GLP-1 apart.
-   **Fatty acid side chain** — lets the molecule bind albumin, a blood protein, so it circulates longer.
-   **Linker tweaks** — tuned how tightly it binds albumin without losing receptor activity.

The result was a half-life of roughly one week, per the [FDA's Ozempic approval package](https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209637Orig1s000TOC.cfm). That's why semaglutide injections are dosed once weekly. Phase 2 human trials of the weekly version began in 2008.

## Finding 3: SUSTAIN-6 Showed Heart Safety Before Approval

After 2008, the FDA began requiring diabetes drugs to prove they don't raise heart risk. Semaglutide went through that test in SUSTAIN-6.

The trial enrolled 3,297 adults with type 2 diabetes and high cardiovascular risk. Over about two years, the semaglutide group had a **26% lower relative risk** of major heart events than placebo. That composite covered heart attack, stroke and cardiovascular death, as reported in [The New England Journal of Medicine in 2016](https://www.nejm.org/doi/full/10.1056/NEJMoa1607141).

SUSTAIN-6 was designed for safety, not to prove benefit. Still, it was an early signal that semaglutide's effects went beyond blood sugar. It also flagged a higher rate of diabetic eye complications in some patients, which providers still screen for.

## Finding 4: 2017 Was the First FDA Approval

On December 5, 2017, the FDA approved **Ozempic** (semaglutide injection). It was approved to improve blood sugar control in adults with type 2 diabetes. This is the date most people mean when they ask how long semaglutide has been around.

The approval drew on the SUSTAIN clinical program. Those trials compared semaglutide with placebo and with other diabetes drugs, including sitagliptin, exenatide and insulin glargine.

In 2019, the FDA approved **Rybelsus**, a daily semaglutide tablet. It was the first GLP-1 medication you could swallow instead of inject. The PIONEER trials supported that approval.

## Finding 5: STEP 1 Moved Semaglutide Into Weight Management

Weight loss showed up in the diabetes trials as a side effect. Researchers then tested a higher dose, 2.4 mg weekly, specifically for weight.

STEP 1 enrolled 1,961 adults with obesity or overweight who did not have diabetes. Everyone also got lifestyle counseling. At 68 weeks, the semaglutide group's mean body-weight change was **−14.9%**, versus −2.4% with placebo, per the [2021 NEJM report](https://www.nejm.org/doi/full/10.1056/NEJMoa2032183).

Those are averages across a large group. Some participants saw more change, some saw less, and individual results vary. The most common side effects were nausea, diarrhea, vomiting and constipation, mostly mild to moderate and most frequent during dose increases.

On June 4, 2021, the FDA approved **Wegovy** for chronic weight management. It was the first new weight-management drug approval since 2014.

Curious how this research applies to you? You can [review TelosRX's GLP-1 options](https://www.telosrx.com/pages/glp-1-options). Any prescription is subject to medical approval by a licensed provider after an asynchronous online evaluation.

## Finding 6: SELECT Linked Semaglutide to Fewer Heart Events in People Without Diabetes

SUSTAIN-6 studied people with diabetes. SELECT asked a bigger question: what about people with obesity and heart disease, but no diabetes?

The trial followed 17,604 adults for a mean of about 40 months. Semaglutide 2.4 mg was linked to a **20% lower relative risk** of major heart events versus placebo, according to [the 2023 NEJM publication](https://www.nejm.org/doi/full/10.1056/NEJMoa2307563).

In March 2024, the FDA added a cardiovascular risk-reduction indication to Wegovy's label for adults with established heart disease and obesity or overweight. That shifted how many clinicians think about the drug. It's not only a weight tool anymore.

## Finding 7: FLOW Added Kidney Outcome Data

Chronic kidney disease is common in type 2 diabetes. The FLOW trial tested whether semaglutide changed kidney outcomes in 3,533 people with both conditions.

The trial stopped early for efficacy. Semaglutide 1 mg weekly was linked to a **24% lower relative risk** of major kidney events versus placebo. Those included kidney failure and large losses of kidney function, per the [2024 NEJM results](https://www.nejm.org/doi/full/10.1056/NEJMoa2403347).

In January 2025, the FDA expanded Ozempic's label to cover kidney risk reduction. It applies to adults with type 2 diabetes and chronic kidney disease.

## Finding 8: 2025 Brought Liver and Oral Weight-Management Approvals

Two more milestones landed in 2025. In August, the FDA granted accelerated approval to Wegovy for MASH, a form of fatty liver disease with liver scarring. That decision rested on interim data from the ESSENCE trial.

In December 2025, the FDA approved an oral semaglutide tablet for chronic weight management. That gave people a once-daily pill option alongside the weekly injection. We cover how the pill compares in our [oral vs injectable semaglutide guide](https://www.telosrx.com/blogs/glp1/oral-semaglutide-vs-injectable-semaglutide).

Research continues in other areas too, including knee osteoarthritis pain, heart failure symptoms and addiction-related behaviors. Some of those results are promising. Others, like recent Alzheimer's trials, did not show the hoped-for benefit. Not every lead pans out.

## What About Compounded Semaglutide?

Compounded semaglutide entered the picture during the national shortage of 2022 to early 2025. Licensed pharmacies prepared it so patients could keep access while branded supply was short. The FDA announced the shortage was resolved in February 2025.

Here's the key fact: **compounded semaglutide is not FDA-approved**. It contains the same active ingredient, but it has not gone through the FDA review that Ozempic, Wegovy and Rybelsus did. The trial results above apply to the branded products studied.

Our explainer on [what compounded semaglutide is](https://www.telosrx.com/blogs/glp1/what-is-compounded-semaglutide) covers sourcing, safety checks and how it differs from brand-name options.

## What the Research Does Not Show (Yet)

Nine years on the market is a solid track record. It's not a lifetime. A few open questions remain:

-   **Very long-term use.** Most large trials ran two to four years. Decades-long data don't exist yet.
-   **Stopping the drug.** The STEP 1 extension found much of the weight returned within a year of stopping. Our guide on [what happens when you stop semaglutide](https://www.telosrx.com/blogs/glp1/what-happens-when-you-stop-taking-semaglutide) explains why.
-   **Muscle and bone.** Weight loss includes some lean mass. Researchers are still studying how best to protect it.
-   **Rare side effects.** Pancreatitis, gallbladder issues and a boxed warning about thyroid C-cell tumors in rodents remain on the label. Your provider screens for these.

The honest summary: semaglutide is one of the most studied drugs in modern metabolic medicine. It still has unknowns, like every drug.

## Frequently Asked Questions

### When was semaglutide first approved?

The FDA first approved semaglutide on December 5, 2017, as Ozempic for adults with type 2 diabetes. Rybelsus, the daily tablet, followed in 2019. Wegovy, the higher-dose injection for chronic weight management, was approved in June 2021. So semaglutide has been on the US market for about nine years.

### Is semaglutide FDA-approved for weight loss?

Yes, as the brand Wegovy. The FDA approved it for chronic weight management in 2021, alongside diet and physical activity. An oral version for weight management was approved in December 2025. Ozempic and Rybelsus are approved for type 2 diabetes. Compounded semaglutide is not FDA-approved, even though it shares the same active ingredient.

### Is Mounjaro a semaglutide?

No. Mounjaro and Zepbound contain tirzepatide, a different molecule made by a different company. Tirzepatide acts on two hormone receptors, GLP-1 and GIP. Semaglutide acts on GLP-1 only. Both are weekly injections, but they are separate drugs with separate trial programs and labels.

### How long has semaglutide been studied in humans?

Phase 2 human trials of once-weekly semaglutide began in 2008. That means semaglutide has been studied in people for nearly two decades. The broader GLP-1 research behind it goes back to the 1980s. Large outcome trials like SUSTAIN-6, SELECT and FLOW have added years of follow-up data.

### What is semaglutide used for?

FDA-approved semaglutide brands cover several uses. These include blood sugar control in type 2 diabetes and chronic weight management. They also include heart risk reduction, kidney risk reduction and MASH with liver fibrosis in specific adults. Each indication belongs to a specific brand and dose, so the exact use depends on the product.

### Is semaglutide safe long term?

Trials lasting up to four years show a generally consistent safety profile. Stomach side effects are the most common. Rare risks include pancreatitis and gallbladder problems. Decades-long data don't exist yet. A licensed provider reviews your history before prescribing and monitors you over time.

### How fast does semaglutide work?

Blood sugar effects can show within the first weeks. Weight changes build more slowly because the dose is increased step by step over about four months. In STEP 1, average weight change continued through week 60 before leveling off. Individual timelines vary widely.

_TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service._

Start your private evaluation at [TelosRX](https://telosrx.com).

**Tags:** GLP-1 research, how long has semaglutide been around, Ozempic approval, research review, SELECT trial, semaglutide history, Wegovy

---

> Source: [Telos RX](https://www.telosrx.com/blogs/glp1/how-long-has-semaglutide-been-around)
